Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,9974186,tissue-to-plasma ratio,"At 24 hr, the mean tissue-to-plasma ratio of tiludronate for aorta was 1.2-1.6.",Pharmacokinetics of bisphosphonates in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9974186/),,1.2-1.6,30424,DB01133,Tiludronate
,8911885,minimal plasma concentrations (Cmin),"Following the final dose on Day 12, minimal plasma concentrations (Cmin) ranged between 0.19 and 1.5 mg.1(-1), and maximal plasma concentrations (Cmax) between 1.1 and 7.8 mg.1(-1) for the lowest and highest doses, respectively.",Multiple dose pharmacokinetics of tiludronate in healthy volunteers. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8911885/),mg,0.19 and 1.5,53424,DB01133,Tiludronate
,8911885,maximal plasma concentrations (Cmax),"Following the final dose on Day 12, minimal plasma concentrations (Cmin) ranged between 0.19 and 1.5 mg.1(-1), and maximal plasma concentrations (Cmax) between 1.1 and 7.8 mg.1(-1) for the lowest and highest doses, respectively.",Multiple dose pharmacokinetics of tiludronate in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8911885/),mg,1.1 and 7.8,53425,DB01133,Tiludronate
,18307502,Bioavailability,Bioavailability of the CRI was 103% (not significantly different) that of the 10 daily i.v. bolus doses.,Comparative pharmacokinetics of two intravenous administration regimens of tiludronate in healthy adult horses and effects on the bone resorption marker CTX-1. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18307502/),%,103,85016,DB01133,Tiludronate
,8573422,absolute bioavailability,An absolute bioavailability of approximately 6% has been reported with large inter- and intra-subject variability.,Human pharmacokinetics of tiludronate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8573422/),%,6,165181,DB01133,Tiludronate
,8573422,elimination half-life,"The elimination half-life in patients with normal renal function is approximately 40-60 h, but is significantly increased in subjects with severe renal impairment.",Human pharmacokinetics of tiludronate. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8573422/),h,40-60,165182,DB01133,Tiludronate
,8573422,renal clearance,The renal clearance (0.7 L/h) is independent of dose and suggests that glomerular filtration is the mechanism responsible for elimination.,Human pharmacokinetics of tiludronate. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8573422/),[l] / [h],0.7,165183,DB01133,Tiludronate
